Experimental drug ACP-196 takes on recurrent glioblastoma
NCT ID NCT02586857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called ACP-196 (acalabrutinib) in 24 adults with recurrent glioblastoma, an aggressive brain cancer that has returned after standard treatment. Participants take the drug by mouth once or twice daily. The main goal is to see if the drug can shrink tumors or stop them from growing, while also checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACP-196 (acalabrutinib)
What this could lead to
If successful, this could point toward a new treatment option for recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong
This is an early-phase trial with only 24 participants, so results may not apply broadly. The drug may not shrink tumors or improve survival, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Los Angeles, California, 90095-1769, United States
-
Research Site
Palo Alto, California, 94304, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
Boston, Massachusetts, 2215, United States
-
Research Site
New York, New York, 10021, United States
-
Research Site
Vancouver, Washington, 98684, United States